FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128707719> ?p ?o ?g. }

• W2128707719 endingPage "1217" @default.
• W2128707719 startingPage "1213" @default.
• W2128707719 abstract "In the UK, primary varicella is usually a mild infection in children, but can cause serious illness in susceptible pregnant women and adults. The UK Joint Committee on Vaccination and Immunisation is considering an adolescent varicella vaccination programme. Cost-effectiveness depends upon identifying susceptibles and minimising vaccine wastage, and chickenpox history is one method to screen for eligibility. To inform this approach, we estimated the proportion of adolescents with varicella antibodies by reported chickenpox history.Recruitment occurred through secondary schools in England from February to September 2012. Parents were asked about their child's history of chickenpox, explicitly setting the context in terms of the implications for vaccination. 247 adolescents, whose parents reported positive (120), negative (77) or uncertain (50) chickenpox history provided oral fluid for varicella zoster virus-specific immunoglobulin-G (VZV-IgG) testing.109 (90.8% [85.6-96.0%]) adolescents with a positive chickenpox history, 52 (67.5% [57.0-78.1%]) with a negative history and 42 (84.0% [73.7-94.3%]) with an uncertain history had VZV-IgG suggesting prior infection. Combining negative and uncertain histories, 74% had VZV-IgG (best-case). When discounting low total-IgG samples and counting equivocals as positive (worst-case), 84% had VZV-IgG. We also modelled outcomes by varying the negative predictive value (NPV) for the antibody assay, and found 74-87% under the best-case and 84-92% under the worst-case scenario would receive vaccine unnecessarily as NPV falls to 50%.Reported chickenpox history discriminates between varicella immunity and susceptibility in adolescents, but significant vaccine wastage would occur if this approach alone were used to determine vaccine eligibility. A small but important proportion of those with positive chickenpox history would remain susceptible. These data are needed to determine whether reported history, with or without oral fluid testing in those with negative and uncertain history, is sufficiently discriminatory to underpin a cost-effective adolescent varicella vaccination programme." @default.
• W2128707719 created "2016-06-24" @default.
• W2128707719 creator A5001471272 @default.
• W2128707719 creator A5008173791 @default.
• W2128707719 creator A5026326164 @default.
• W2128707719 creator A5054039682 @default.
• W2128707719 creator A5059133452 @default.
• W2128707719 creator A5061924656 @default.
• W2128707719 creator A5072485453 @default.
• W2128707719 creator A5085665804 @default.
• W2128707719 creator A5087209063 @default.
• W2128707719 date "2014-02-01" @default.
• W2128707719 modified "2023-10-14" @default.
• W2128707719 title "Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England" @default.
• W2128707719 cites W1554104503 @default.
• W2128707719 cites W1936398933 @default.
• W2128707719 cites W1964147 @default.
• W2128707719 cites W1970562837 @default.
• W2128707719 cites W1970891411 @default.
• W2128707719 cites W1994660424 @default.
• W2128707719 cites W1995246983 @default.
• W2128707719 cites W2009446072 @default.
• W2128707719 cites W2024312400 @default.
• W2128707719 cites W2024431235 @default.
• W2128707719 cites W2025115357 @default.
• W2128707719 cites W2039256872 @default.
• W2128707719 cites W2049276348 @default.
• W2128707719 cites W2055378097 @default.
• W2128707719 cites W2056934342 @default.
• W2128707719 cites W2067301960 @default.
• W2128707719 cites W2067450634 @default.
• W2128707719 cites W2132149002 @default.
• W2128707719 cites W2149170181 @default.
• W2128707719 cites W2163470216 @default.
• W2128707719 cites W2343825548 @default.
• W2128707719 cites W2976875521 @default.
• W2128707719 cites W4211188326 @default.
• W2128707719 cites W4256558354 @default.
• W2128707719 cites W47776034 @default.
• W2128707719 doi "https://doi.org/10.1016/j.vaccine.2013.06.098" @default.
• W2128707719 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3969712" @default.
• W2128707719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23871823" @default.
• W2128707719 hasPublicationYear "2014" @default.
• W2128707719 type Work @default.
• W2128707719 sameAs 2128707719 @default.
• W2128707719 citedByCount "13" @default.
• W2128707719 countsByYear W21287077192014 @default.
• W2128707719 countsByYear W21287077192015 @default.
• W2128707719 countsByYear W21287077192016 @default.
• W2128707719 countsByYear W21287077192017 @default.
• W2128707719 countsByYear W21287077192018 @default.
• W2128707719 countsByYear W21287077192019 @default.
• W2128707719 crossrefType "journal-article" @default.
• W2128707719 hasAuthorship W2128707719A5001471272 @default.
• W2128707719 hasAuthorship W2128707719A5008173791 @default.
• W2128707719 hasAuthorship W2128707719A5026326164 @default.
• W2128707719 hasAuthorship W2128707719A5054039682 @default.
• W2128707719 hasAuthorship W2128707719A5059133452 @default.
• W2128707719 hasAuthorship W2128707719A5061924656 @default.
• W2128707719 hasAuthorship W2128707719A5072485453 @default.
• W2128707719 hasAuthorship W2128707719A5085665804 @default.
• W2128707719 hasAuthorship W2128707719A5087209063 @default.
• W2128707719 hasBestOaLocation W21287077191 @default.
• W2128707719 hasConcept C159047783 @default.
• W2128707719 hasConcept C159654299 @default.
• W2128707719 hasConcept C187212893 @default.
• W2128707719 hasConcept C203014093 @default.
• W2128707719 hasConcept C22070199 @default.
• W2128707719 hasConcept C2522874641 @default.
• W2128707719 hasConcept C2776159415 @default.
• W2128707719 hasConcept C2776334287 @default.
• W2128707719 hasConcept C2780473352 @default.
• W2128707719 hasConcept C2780801004 @default.
• W2128707719 hasConcept C2908772859 @default.
• W2128707719 hasConcept C71924100 @default.
• W2128707719 hasConceptScore W2128707719C159047783 @default.
• W2128707719 hasConceptScore W2128707719C159654299 @default.
• W2128707719 hasConceptScore W2128707719C187212893 @default.
• W2128707719 hasConceptScore W2128707719C203014093 @default.
• W2128707719 hasConceptScore W2128707719C22070199 @default.
• W2128707719 hasConceptScore W2128707719C2522874641 @default.
• W2128707719 hasConceptScore W2128707719C2776159415 @default.
• W2128707719 hasConceptScore W2128707719C2776334287 @default.
• W2128707719 hasConceptScore W2128707719C2780473352 @default.
• W2128707719 hasConceptScore W2128707719C2780801004 @default.
• W2128707719 hasConceptScore W2128707719C2908772859 @default.
• W2128707719 hasConceptScore W2128707719C71924100 @default.
• W2128707719 hasIssue "10" @default.
• W2128707719 hasLocation W21287077191 @default.
• W2128707719 hasLocation W21287077192 @default.
• W2128707719 hasLocation W21287077193 @default.
• W2128707719 hasLocation W21287077194 @default.
• W2128707719 hasLocation W21287077195 @default.
• W2128707719 hasLocation W21287077196 @default.
• W2128707719 hasOpenAccess W2128707719 @default.
• W2128707719 hasPrimaryLocation W21287077191 @default.
• W2128707719 hasRelatedWork W1953041445 @default.
• W2128707719 hasRelatedWork W1970769167 @default.

• next